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DOI 10.1016/j.ccr.2010.09.007SUMMARYThe global impairment of mature microRNAs (miRNAs) is emerging as a common feature of human tumors.
One interesting scenario is that defects in the nuclear export of precursor miRNAs (pre-miRNAs) might occur
in transformed cells. Exportin 5 (XPO5) mediates pre-miRNA nuclear export and herein we demonstrate the
presence of XPO5-inactivating mutations in a subset of human tumors with microsatellite instability. The
XPO5 genetic defect traps pre-miRNAs in the nucleus, reduces miRNA processing, and diminishes
miRNA-target inhibition. The XPO5 mutant form lacks a C-terminal region that contributes to the formation
of the pre-miRNA/XPO5/Ran-GTP ternary complex and pre-miRNAs accumulate in the nucleus. Most impor-
tantly, the restoration of XPO5 functions reverses the impaired export of pre-miRNAs and has tumor-
suppressor features.INTRODUCTION
MicroRNAs (miRNAs) are small noncoding RNAs that regulate
gene expression by targeting messenger RNA (mRNA) tran-
scripts. MiRNAs play important roles in several cellular
processes by simultaneously controlling the expression levels
of hundreds of genes (He and Hannon, 2004; Bartel, 2004;
Chang and Mendell, 2007). In human cancer, miRNA expression
profiles differ between normal tissues and derived tumors and
between tumor types (Lu et al., 2005; Volinia et al., 2006), and
it has been shown that miRNAs can act as oncogenes or tumorSignificance
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Deficient Export of Pre-miRNAsthe TARBP2miRNA processing gene (Melo et al., 2009). This last
finding is particularly relevant because if the factors involved in
miRNA processing pathways are themselves targets of genetic
disruption, they might represent another class of tumor-
suppressor genes. In this regard, there is an enhancement of
tumorigenesis upon depletion of DICER1 in human cells (Kumar
et al., 2007) and heterozygous deletion of DICER1 in mice
(Kumar et al., 2007, 2009; Lambertz et al., 2010). Moreover,
reduced DICER1 expression occurs in lung and ovarian tumors
(Karube et al., 2005; Merritt et al., 2008). Under these circum-
stances, DICER1 might be described as a haploinsufficient
tumor-suppressor gene that is heterozygously deleted in cancer
(Kumar et al., 2009). Most importantly, Hill et al. (2009) have iden-
tified DICER1 germline mutations in an inherited cancer
syndrome, familial pleuropulmonary blastoma.
The biogenesis of miRNAs in mammalian cells involves both
nuclear and cytoplasmic processing (Lee et al., 2002) catalyzed
by ribonuclease III (RNase III)-like endonucleases that recognize
double-stranded RNAs. miRNAs are initially transcribed as long
RNAs, termed primary miRNAs (pri-miRNAs), that contain the
mature miRNA as one arm of an RNA stem-loop (Lee et al.,
2002). This stem-loop is excised by the nuclear RNase III enzyme
DROSHA to give an 65 nt RNA hairpin, bearing a 2 nt 30 over-
hang, termed a precursor-miRNA (pre-miRNA) (Zeng and Cullen,
2004). The pre-miRNAs generated in the nucleus require further
processing in the cytoplasm, and so the nucleocytoplasmic
transport of pre-miRNAs is essential for the maturation process
of the miRNAs (Yi et al., 2003; Bohnsack et al., 2004; Kim, 2004;
Lund et al., 2004).
One of the key elements in the nuclear export of pre-miRNAs is
Exportin-5 (XPO5) (Lund et al., 2004). XPO5 is a member of the
karyopherin b family related to human export receptor CRM1
that uses the GTPase Ran to control cargo association (Smith
et al., 2002; Bohnsack et al., 2004). Nuclear export of pre-miR-
NAs is tightly regulated in normal cells and its disruption would
also cause the observed phenotype of global downregulation
of mature microRNAs in cancer cells. Strikingly, a recent report
has demonstrated that some pre-miRNAs are retained in the
nucleus of several cancer cell lines (Lee et al., 2008), reinforcing
the hypothesis that genetic defects in the pre-miRNA nuclear
export genes might occur in human tumors.
Here, we investigated whether genes involved in the export of
the pre-miRNAs, such as XPO5, undergo loss-of-function muta-
tions in human tumors and the functional significance of such
inactivation in nucleocytoplasmic pre-miRNA shuttling and
cellular transformation.
RESULTS
Detection of an XPO5-Inactivating Mutation in Human
Cancer Cells
In order to explore the existence of inactivating mutations in the
process of nucleocytoplasmic export of pre-miRNAs, we
decided to consider tumors that exhibit microsatellite instability,
in the contexts of hereditary nonpolyposis colon cancer
(HNPCC) associated with germline mutations in the mismatch
repair genes and of sporadic cancers associated with hMLH1
inactivation by promoter CpG island methylation. Tumors with
microsatellite instability progress along a genetic pathway with304 Cancer Cell 18, 303–315, October 19, 2010 ª2010 Elsevier Inc.a high rate of insertion and deletionmutations in mononucleotide
repeats, which often results in the generation of premature stop
codons. Illustrative target genes include the growth control gene
TGFBR2 (Markowitz et al., 1995) and the proapoptotic geneBAX
(Rampino et al., 1997).
We first screened six colorectal (Co115, RKO, SW48, LoVo,
HCT-15, DLD-1, and HCT-116), four endometrial (SKUT-1,
SKUT-1B, AN3CA, and HEC1B), and two gastric (SNU-1 and
SNU-638) cancer cell lines with microsatellite instability for the
presence of mutations in all the exonic mononucleotide repeats
present in the coding sequences of the two main genes involved
in the export of the pre-miRNAs from the nucleus: exportin 5
(XPO5) and Ras-related nuclear protein (RAN). We detected
only wild-type sequences for RAN (Figure S1) but found a frame-
shift mutation in XPO5: the insertion of an ‘‘A’’ in an (A)7 coding
microsatellite repeat of exon 32 (position 3546 bp) in the colo-
rectal cancer cell lines HCT-15 and DLD-1 (Figure 1A). The inser-
tion generates a premature termination codon at position
3582 bp. The protein originated from the mutated transcript
has altered amino acids 1181–1192 and truncated amino acids
1193–1205. The mutation was present in 24 of 48 (50%) and
25 of 48 (52%) single clone sequences obtained from genomic
DNA for HCT-15 and DLD-1, respectively. The same proportion
of mutant alleles was found when we used cDNA as the starting
material, which indicates that they are heterozygous mutations.
The FISH analysis showed that the two alleles were retained in
both cancer cell lines (Figure S1).
The analyses of XPO5 expression by western blot in the total
protein extracts from mutant cell lines HCT-15 and DLD-1
demonstrated the presence of the truncated form of the XPO5
protein (Figure 1B; Figure S1) in addition to the wild-type form.
The mutated XPO5 protein was not present in the wild-type
cell lines SW48, HCT-116, and RKO. Most interestingly, when
we analyzed nuclear and cytoplasmic fractions separately for
XPO5 protein by western blot in the three XPO5-proficient cells
(RKO, HCT-116, and SW48) and two XPO5 mutated cells
(HCT-15 and DLD-1), we found that the truncated form of the
XPO5 protein was exclusively present in the nuclear fraction of
HCT-15 and DLD-1 cell lines (Figure 1B). To reinforce the protein
localization results obtained by western blot, we carried out
immunocytochemistry for the XPO5 protein and observed that
in mutated cells (HCT-15 and DLD-1) the XPO5 protein mainly
accumulated in the nucleus (Figure 1B). XPO5 wild-type cells
(HCT-116 and RKO) show XPO5 staining that spreads equally
throughout the nucleus and the cytoplasm (Figure 1B).
The XPO5 Mutation Traps Precursor microRNAs
in the Nucleus, Decreases Processing Efficiency,
and Diminishes Target Inhibition by miRNAs
Once the presence of an XPO5 mutation associated with
abnormal protein localization in cancer cells had been
confirmed, it became very important to establish, whether the
subcellular distribution of pre-miRNAs was affected as well as
their processing efficiency, the amount of pre-miRNA that is
transformed in its mature form (Experimental Procedures). We
first assessed pre-miRNA cellular localization by the study of
24 pre-miRNAs analyzed by qRT-PCR (Schmittgen et al., 2004)
in isolated nuclear and cytoplasmic fractions. For all the studied
pre-miRNAs, we observed a nuclear accumulation of these
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Figure 1. A Mutant XPO5 in Human Cancer
(A) Diagram of the XPO5 gene, with the location of
the (A)7 repeat. Schematic representation of the
XPO5 wild-type protein, and the mutated form of
XPO5 (the insertion of an ‘‘A’’ in the A7 repeat alters
the open reading frame changing amino acids
1181–1192 and truncating the last 13 amino acids
of the protein—amino acids 1193–1205).
(B) XPO5 protein expression analyzed by western
blot and immunocytochemistry. XPO5 protein
expression using total protein extracts and nuclear
(N) versuscytoplasmic (C) fractionatedextracts are
shown. Only in cell lines harboring the XPO5
mutation was the truncated XPO5 form located
exclusively in the nuclear fraction. Immunocyto-
chemistry shows mainly nuclear XPO5Mut protein
localization in mutant cells (HCT-15 and DLD-1),
while in XPO5 wild-type cells (RKO and HCT-116)
the protein was seen to spread throughout the
nucleus and cytoplasm. Scale bars, 10 mm.
(C) Higher nuclear levels of 24 precursor miRNAs
relative to cytoplasm, quantified by qRT-PCR, are
observed in mutant XPO5 cell lines. In the wild-
type cell lines (RKO and HCT-116), the highest
levels of precursor miRNAs are found in the
cytosol. Data shown represent mean ± SD, n = 3.
(D) Northern blot analysis confirmed the accumula-
tion of pre-miRNA 125-b in the nucleus of XPO5
mutant cells (HCT-15 and DLD-1) in sharp contrast
to XPO5 wild-type cells (RKO and HCT-116) where
it was mainly located in the cytoplasm. U6 and
tRNAMet were used as nuclear and cytoplasmic
loading control, respectively.
See also Figure S1.
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Deficient Export of Pre-miRNAsmolecules in XPO5mutant cells (HCT-15 andDLD-1) (Figure 1C),
while in XPO5 wild-type cells (RKO and HCT-116) the pre-miR-
NAs were found mainly in the cytoplasmic fraction (Figure 1C).
Northern blot analysis for miRNA-125-b confirmed its inefficient
pre-miRNA processing in XPO5 mutant versus wild-type cells
(Figure 1D). Furthermore, we observed that XPO5 mutant cells
featured an overall reduction in the efficiency of processing
each of the 24 pre-miRNAs molecules, defined as the ratio of
mature to precursor miRNA determined by qRT-PCR, relative
to XPO5 wild-type cells (Figure S1). Interestingly, XPO5 might
also be an auxiliary exporter of transfer RNAs (tRNAs) (Bohnsack
et al., 2002; Calado et al., 2002), in parallel to the principal tRNA
exporter Exportin-T (XPOT) (Ko¨hler and Hurt, 2007). We did not
observe an accumulation of tRNAMet assessed by northern blot
in XPO5 mutant cells (HCT-15 and DLD-1) in comparison to
wild-type cells (RKO and HCT-116) (Figure 1D). However, this
observation does not rule out that other tRNAs are affected. InCancer Cell 18, 303–315,fact, XPOT and XPO5 bind quite comple-
mentary sets of tRNAs (Bohnsack et al.,
2002).
To strengthen the evidence of a link
betweenXPO5mutation and the impaired
protein shuttling between nucleus and
cytoplasm and the defective processing
of pre-miRNAs observed, we reconsti-
tuted XPO5 function in XPO5 mutantcancer cells (HCT-15) (Figure S2). XPO5 levels in the ectopically
expressing cells in comparison to the endogenous levels in the
sham/control transfected cells are shown in Figure S2. Transfec-
tion of an N-terminal flag-tagged wild-type form of XPO5 protein
(XPO5WT) in HCT-15 cells showed that the wild-type transfected
protein localizes in the nucleus and cytoplasm (Figure 2A).
However, the transfection of a N-terminal flag-tagged construct
carrying the described XPO5mutation (XPO5Mut) in HCT-15 cells
shows anXPO5protein that it is located inside the nucleus andno
signal is seen in the cytoplasm (Figure 2A). Wild-type endoge-
nous XPO5 localization was unaffected upon mock transfection
(Figure S2). Because the approach described looks at proteins
steady-state levels, we also formally proved that FLAG-XPO5Mut
is trapped in the nucleus using the heterokaryon approach (Lee
et al., 1996). Heterokaryon assays demonstrated that XPO5Mut
is not capable of shuttling between the nucleus and the
cytoplasm of the empty-vector and XPO5Mut N-terminal flagOctober 19, 2010 ª2010 Elsevier Inc. 305
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Figure 2. Transfection of Wild-Type XPO5 Rescues Pre-miRNA Location
(A) XPO5 protein expression was restored after transfecting flagged XPO5 wild-type in HCT-15 cell line. As a control, XPO5 mutant form was also stably trans-
fected in HCT-15. Transfected proteins were detected by immunocytochemistry using an antiflag antibody. XPO5 mutant form presented exclusively nuclear
accumulation by immunocytochemistry. Scale bars, 10 mm.
(B) Heterokaryon assay shows nuclear retention of XPO5Mut protein transfected in HCT-116 cell line (left panel). Positive control for the heterokaryon assay using
wild-type XPO5 is shown in the right panel. DIC, differential interphase contrast. Scale bars, 10 mm.
(C) HCT-15 cell line transfectedwith XPO5WT showed a displacement of the described 24 pre-miRNAs from the nucleus to the cytoplasmwhile no alteration of the
pre-miRNAs localization was seen in XPO5Mut-transfected HCT-15 cells. Data shown represent mean ± SD, n = 3.
(D) Northern blot analysis confirmed the cytoplasmic enrichment of pre-miR-125-b and pre-miR-26-a in XPO5WT HCT-15-restored cells. U6 and tRNAMet were
used as nuclear and cytoplasmic loading control, respectively.
See also Figure S2.
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Figure 3. XPO5 Stable Downregulation and Pharmaceutical Inhibition Mimics the Phenotype of XPO5 Impaired Cells
(A) Protein blot showing stable downregulation of XPO5 protein expression in XPO5-proficient RKO cell line using short-hairpin approach.
(B) XPO5-downregulated RKO cells showed an increased concentration of 24 pre-miRNAs in the nucleus compared with empty vector transfected cells deter-
mined by qRT-PCR.
(C) Northern blot analysis confirmed the nuclear enrichment of pre-let-7a in XPO5 RKO downregulated cells. U6 and tRNAMet were used as nuclear and cyto-
plasmic loading control, respectively.
(D) XPO5 is retained in the nuclear fraction upon delivery of WGA by electroporation. Scale bars, 10 mm.
(E) The inhibition of nuclear export by WGA treatment retains pre-miRNAs in the nuclear fraction of XPO5 wild-type and impairs pre-miRNA processing efficiency
(*1 p = 0.0031, *2 p = 0.0042).
(F) Expression level of pre-miRNAs 15-1 and 16-a in stably transfected cells measured by qRT-PCR analysis.
(G) Transient transfection of 30UTR of Bcl2 under a luciferase reporter in pRS-GFPneo-miR-15-16 stable clones. Only XPO5WT-restored cell lines, together with
RKO XPO5-proficient cell lines, showed significantly lower luciferase activity. NC: control using mutated nonfunctional Bcl2 30UTR. pGL2 basic vector was used
as a empty vector control. One microgram total DNA vector per transfection was used to normalize the diagram.
Data shown represent mean ± SD, n = 3. See also Figure S3.
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Deficient Export of Pre-miRNAstransfected HCT-116 fused cells (Figure 2B). Most importantly,
XPO5mutant cells transfected with the wild-type protein under-
went a relocation of pre-miRNAs from the nucleus to the cytosol
(Figure 2C).Northern blot analyses formiRNA-125-b andmiRNA-
26-a confirmed the described results (Figure 2D). XPO5wild-type
transfection was associated with an increased processing
capacity for the 24 pre-miRNAs determined by qRT-PCR
(Figure S2). Transfection of the mutant form of XPO5 in HCT-15
cells was unable to rescue the phenotype: pre-miRNAs were
essentially located in the nucleus (Figure 2C) and no increase in
pre-miRNA processing efficiency was observed (Figure S2),Cimplying the loss of function features of the identified mutation.
Using primers specific for the 30 pri-miRNAs that originate the
studied 24 pre-miRNAs (details in Experimental Procedures),
we have observed that pri-miRNA levels did not change upon
transfection of the wild-type or mutant XPO5, supporting that
the mutation only affects pre-miRNAs (). tRNAMet (Figure 2D)
levels were also unchanged upon transfection of the wild-type
or mutant XPO5.
In sharp contrast, the stable downregulation of XPO5 by inde-
pendent transfection of three different short-hairpins that targets
XPO5 in cells with wild-type XPO5 (RKO) (Figure 3A; Figure S3)ancer Cell 18, 303–315, October 19, 2010 ª2010 Elsevier Inc. 307
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Deficient Export of Pre-miRNAswas associated with enhanced retention of the studied 24 pre-
miRNAs inside the nucleus (Figure 3B; Figure S3). Northern
blot formiRNA let-7a confirmed the described results (Figure 3C).
An impairment of pre-miRNA processing efficiency was also
observed upon XPO5 depletion (Figure S3). siRNA against the
mutant XPO5 transcript in HCT-15 andDLD-1 cells did not cause
any evident effect in pre-miRNA processing capacity (Figure S3).
Pri-miRNAs (Figure S3) and tRNAMet (Figure 3C) levels were
unchanged upon XPO5 depletion. Furthermore, we were able
to mimic the mutant XPO5 phenotype using wheat germ agglu-
tinin (WGA). WGA blocks nuclear pore complexes by binding
to GlcNac-modified nucleoporins (Mohr et al., 2009). Using elec-
troporation to deliver WGA into the cells (Todorova, 2009), we
observed that XPO5 wild-type cells (RKO and HCT-116) under-
went confinement of the XPO5 protein in the nucleus (Figure 3D),
nuclear accumulation of pre-miRNAs (Figure 3E, left graph), and
decreased pre-miRNA processing efficiency (Figure 3E, right
graph) that closely resemble the phenotype observed in XPO5
mutant cells.
We also wondered whether the impaired nuclear export asso-
ciated with XPO5 mutation had an impact on the inhibitory
efficiency of miRNA target genes. To address this issue, we
stably transfected wild-type, mutant and reconstituted XPO5
cells with pRS-GFPneo-miR-15-16, a vector that produces
apre-miRNA that needs tobenuclear exported in order to bepro-
cessed correctly and give rise to its mature forms (miR-15-a and
miR-16-1) (Figure 3F). To show interaction of themature miRNAs
with its target 30UTR, we transiently transfected to the described
cells the 30UTR of the oncogene Bcl2 under a luciferase reporter,
a knownandvalidated target ofmiR-15-a/16-1 (Calin et al., 2008).
We observed that luciferase activity was significantly decreased
only in XPO5 wild-type (RKO) and XPO5WT-restored (HCT-15)
colorectal cancer cells. No significant effect was demonstrated
in XPO5 mutant cells such as DLD-1 and HCT-15 (Figure 3G).
Most importantly, luciferase activity was also unaffected in
HCT-15cells transfectedwith themutant formofXPO5 (XPO5Mut)
(Figure 3G). Consistent with these data, we also observed
that, following stable EGFP transfection in XPO5WT and
XPO5Mut-HCT-15 cells (Figure S3), a short-hairpin against
EGFP was only able to achieve complete silencing in XPO5WT-
restored cells (Figure S3). qRT-PCR on EGFP mRNA was used
as a quantitative measure of the shRNA efficiency (Figure S3).
XPO5 Mutant Form (XPO5Mut) and the Functional
Impairment of the Pre-miRNA/XPO5/Ran-GTP Complex
Once we had demonstrated that XPO5mutant cells had a defect
with respect to exporting pre-miRNAs out of the nucleus and
consequently an impaired processing efficiency, we sought to
determine why the mutant form of the XPO5 protein is trapped
inside the nucleus. It is well documented that pre-miRNAs are
specifically bound by XPO5, acting in concert with the GTP-
bound form of the Ran cofactor (Bohnsack et al., 2004; Lund
et al., 2004; Yi et al., 2003). Since cargo binding to XPO5 is
promoted by Ran-GTP, we decided first to establish whether
Ran could bind the XPO5Mut form. We performed GST pull-
down experiments with recombinant proteins purified from
Escherichia coli in the absence or presence of the cargo, the
pre-miRNAmolecule pre-let-7a. First, as expected, we observed
that the addition of pre-let-7a increased the affinity of the poly-308 Cancer Cell 18, 303–315, October 19, 2010 ª2010 Elsevier Inc.histidine-tagged XPO5WT to bind GST-Ran in a GTP-dependent
manner (Figure 4A, lanes 1 and 2). However, the polyhistidine-
tagged XPO5 mutant form, although also able to bind to GST-
Ran in aGTP-dependent manner, did not show any cooperativity
for Ran binding in the presence of cargo (pre-let-7a) (Figure 4A,
lanes 3 and 4). As a negative control, we used a construct lacking
108 amino acids at the N-terminal domain of XPO5 (XPO5D108)
that is responsible for Ran-GTP coupling (Brownawell and
Macara, 2002) (Figure 4A, lanes 5 and 6). Our findings are in
agreement with previous observations that described Ran/GTP
coupled to the N-terminal of XPO5 protein (Brownawell and
Macara, 2002). This domain is not altered in the XPO5Mut form
that we describe herein. Knowing that a ternary complex of
pre-miRNA/XPO5/Ran-GTP is necessary for efficient nuclear
export (Zeng and Cullen, 2004), we decided to analyze the
capacity of XPO5WT and XPO5Mut forms to bind pre-miRNAs
molecules using the pre-miRNA molecule pre-let-7a.
We transfected a 30-biotin labeled synthetic pre-let-7a in XPO5
mutant HCT-15 cells stably transfected with the empty vector
(pcDNA3.1+), the FLAG-XPO5 wild-type (FLAG-XPO5WT) and
the FLAG-XPO5 mutant (FLAG-XPO5Mut) forms, followed by
FLAG-XPO5 protein and pre-let-7a cellular localization by immu-
nodetection of Flag and biotin, respectively. In empty vector
transfected cells, we observed that pre-let-7a is maintained
within the nucleus after transfection during a 2 hr period (Fig-
ure 4B, left panels and left graph). In HCT-15 cells with reconsti-
tuted XPO5 activity (FLAG-XPO5WT), however, we observed
efficient export of the labeled pre-let-7a into the cytoplasm 1 hr
after transfection and disappearance of the biotin signal in the
cytoplasm 2 hr after transfection (Figure 4B). Furthermore,
XPO5WT flag-tagged protein was found in the same cellular
compartment with pre-let-7a throughout the 2 hr after transfec-
tion translocating from the nucleus to the cytoplasm 1 hr after
transfection (Figure 4B). The same results for XPO5 wild-type
context had been reported for pre-miR-31 export (Bohnsack
et al., 2004). When the same assay was developed on HCT-15
FLAG-XPO5Mut transfected cells, pre-let-7a was not efficiently
transported into the cytoplasm, and 2 hr after transfection there
was still biotin labeling inside the nucleus (Figure 4B). Results of
pre-let-7a levels obtained by qPCR of fractionated nuclear and
cytoplasmic samples confirmed the immunocytochemistry data
(Figure 4C). Furthermore, XPO5Mut flag-tagged protein showed
no translocation to the cytoplasm but stayed in the nucleus for
the 2 hr period (Figure 4B, right panel antiflag labeling). As
a control for the transfection procedure, the staining for the
XPO5 endogenous protein demonstrated that its main nuclear
localization in the HCT-15 mutant cells was unchanged right
before and immediately after pre-let-7a transfection (Figure S4).
Once the impairment of pre-let-7a exportmediated by a defec-
tive XPO5 protein had been demonstrated, we tested the
capacity of the XPO5 mutant form to bind pre-let-7a in a Ran-
GTP-dependent manner. For this purpose, we used the 30
biotin-labeled synthetic pre-let-7a to incubate with purified,
recombinant His-tagged human XPO5WT, XPO5Mut, and re-
combinant Ran in the presence of GTP. We determined by gel
shift analysis that the biotin labeled pre-let-7a did not bind
XPO5Mut in the presence of Ran and GTP (Figure 4D). However,
pre-let-7a formed a readily detectable complex when incubated
with XPO5WT (Figure 4D). To reinforce the specificity of the
Input (5%) 
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Figure 4. XPO5 Mutant and the Functional Impairment of the Pre-miRNA/XPO5/Ran-GTP Complex
(A) GST-Ran fusion protein was incubated with His-XPO5WT andHis-XPO5Mut in the presence of GTP and in the absence or presence of the cargo, the pre-miRNA
molecule pre-let-7a. Both wild-type andmutant forms of XPO5were able to bind to Ran in a GTP-dependentmanner (lanes 1, 2 and 3, 4, respectively). As a nega-
tive control we used a cloned XPO5 protein lacking the first 108 amino acids (N-terminal) responsible for binding to Ran (XPO5D108, lanes 5 and 6). The addition of
pre-let-7a (lane 2 versus lane 1) increased the affinity of XPO5WT to bind GST-Ran in a GTP-dependent manner. The XPO5 mutant form did not show any
cooperativity for Ran binding in the presence of cargo (pre-let-7a) (lane 4 versus lane 3).
(B) 30 Biotin-labeled pre-let-7a molecule was transfected in empty vector, XPO5WT and XPO5Mut HCT-15 stable transfected cell lines. Upon transfection, and
during a 2 hr period, pre-let-7a and FLAG-XPO5WT or FLAG-XPO5Mut proteins were followed by immunocytochemistry using antibiotin and antiflag staining,
respectively. The graphs on the bottom illustrate the quantification of fluorescence signal in the cytoplasm over time. Only in XPO5WT HCT-15 restored cell
line there is an increase in cytoplasmic signal 1 hr after transfection due to pre-let-7a[Biotin] nuclear export. Scale bars, 10 mm.
(C) qRT-PCR of pre-let-7a. Only in XPO5WTHCT-15 restored cell line there is a pre-let-7a displacement from the nucleus to the cytoplasm at 1 hr posttransfection.
Data shown represent mean ± SD, n = 3.
(D) Gel shift assays were performed with pre-let-7a probe, 30 biotin-labeled, and 3 mM of each recombinant XPO5WT and XPO5Mut in the presence of Ran protein
and GTP. The specific RNA-protein complexes are indicated by arrows. Only XPO5WT is able to bind pre-let-7a specifically. A supershift signal is seen when anti-
His antibody is added to the reaction when using XPO5WT. XPO5Mut form is not able to bind pre-let-7a.
(E) Isothermal titration calorimetry data for XPO5WT and XPO5Mutwith pre-let-7a in the presence or absence of RanGTP. The upper panels show the calorimetric
titrations for 10 ml injections with 240 s time lapses. The lower panels represent the integrated heat values as a function of the protein/pre-miRNAmolar ratio in the
calorimetric cell. An exothermic reaction (DH=9.08 Kcal/mol) is perceived between XPO5WT protein and pre-let-7a in the presence of RanGTPwhile no reaction
takes place between XPO5Mut and pre-let-7a. Both XPO5WT and XPO5Mut fail to bind pre-let-7a in the absence of RanGTP. See also Figure S4.
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Deficient Export of Pre-miRNAsformed RNA-protein complex, we wondered whether unlabeled
competitor RNA would block complex formation if added in
excess, and whether a supershift could be observed when the
antihistidine antibody was added to the reaction. Formation of
the pre-let-7a/XPO5/Ran-GTP complex was indeed inhibited
when the unlabeled competitor RNA was used and a supershift
was observed when antihistidine antibody was added to the
reaction (Figure 4D). Most importantly, the same binding results
were obtained by calorimetric assays (Figure 4E). The precursor
let-7a molecule reacts exothermically (DH = 9.08 Kcal/mol)Cwith XPO5WT protein in the presence of Ran-GTP, while no reac-
tion was observed between the XPO5Mut form and the precursor
miRNA molecule (Figure 4E). The XPO5WT and XPOMut proteins
did not bind pre-let-7a in the absence of Ran-GTP (Figure 4E).
We also analyzed if the mutant XPO5 protein was in any way
able to interfere in the binding of the wild-type XPO5 protein to
its pre-miRNA substrates. Using both EMSA and calorimetric
studies to assess the binding of the wild-type XPO5 protein to
pre-let-7a in the presence of the XPO5 mutant protein and
Ran-GTP, we observed that the binding to the pre-miRNAancer Cell 18, 303–315, October 19, 2010 ª2010 Elsevier Inc. 309
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Deficient Export of Pre-miRNAssubstrate was not affected by the presence of the XPO5 mutant
protein (Figure S4).
Overall, these results suggest that a region in the C-terminal of
XPO5 protein is involved in the binding and/or recognition of pre-
miRNAs as a cargo substrate. In XPO5 mutant cells, such as
HCT-15 and DLD-1, the protein is not able to load the precursor
miRNA molecule, the pre-miRNA/XPO5/Ran-GTP ternary
complex cannot be assembled and pre-miRNAs accumulate in
the nucleus.
Tumor-Suppressor Features of the XPO5 Protein
Once we had demonstrated how the described XPO5 mutation
in cancer cells impaired the export of pre-miRNAs, we wished
to determine its contribution to the tumorigenic phenotype.
Thus, we took a triple approach to show how XPO5 genetic
disruption causes a defect in the expression of mature miRNAs
with tumor-suppressor features, how its restoration leads to
cancer growth inhibition both in vitro and in vivo, and how
XPO5 mutations are present in human primary tumors.
We first analyzed the miRNA expression profile of wild-type
(RKO and HCT-116), mutant (HCT-15 and DLD-1), reconstituted
(HCT-15 and DLD-1 XPO5WT), and mutant transfected (HCT-15
and DLD-1 XPO5Mut) XPO5 cell lines using a comprehensive
expression miRNA microarray platform that covers 731 miRNAs
(Calin et al., 2007). Among these, the expression of around 50%
miRNAs was initially absent in the colorectal cancer cell lines
RKO (n = 449), HCT-116 (n = 448), DLD-1 (n = 421), and HCT-
15 (n = 398). We used Class Comparison (p < 0.001) to identify
the miRNAs differentially expressed between classes, and Class
Prediction (p < 0.001, repeated 100 times, K-fold cross-valida-
tion method, where K = 10) to identify patterns of miRNAs that
can discriminate groups of samples. The two XPO5 mutant cell
lines were characterized as having a significant downregulation
of 85 miRNAs compared with the two wild-type XPO5 cell lines
(Figure 5A). Most importantly, the reintroduction of XPO5 in the
mutant cells upregulated 114 miRNAs (Figure 5A, HeatMap)
that included 80 of 85 (94%) of the described miRNAs. qRT-
PCR was used to validate the microarray data for 11 miRNAs
(six miRNAs upregulated in XPO5WT-transfected cells and five
miRNAs with similar levels) (Figure 5B). We did not observe
any shift in the miRNA expression profile when the XPO5mutant
cells were transfected with the XPO5Mut form. Strikingly, for
these 80 miRNAs downregulated in XPO5 mutant cells and
whose expression is restored in reconstituted cells, 76.8%
have potential tumor-suppressor features (Figure 5C; Medina
and Slack, 2008; Spizzo et al., 2009). Most importantly, this
impairment of tumor-suppressor miRNAs in XPO5 mutant cells
is associated with the upregulation of their respective target on-
coproteins that is reverted by the transfection of wild-type XPO5,
such as we observed for EZH2 (miR-26a), MYC (miR-192, miR-
215, let-7, and miR-24), and K-RAS (miR-192, miR-215, and
let-7) (Figure 5D). One of the best examples was the miR-200
family of tumor-suppressor miRNAs that targets ZEB1, a known
inhibitor of E-cadherin (CDH1) expression (Burk et al., 2008). The
miR-200 family was downregulated in XPO5 mutant cells and,
upon XPO5 transfection, we did not only observe upregulation
of the miR-200 transcripts, but also downregulation of ZEB1
and upregulation of its targets E-cadherin, CRB3, INADL, and
LGL2 (Burk et al., 2008; Figure 5E).310 Cancer Cell 18, 303–315, October 19, 2010 ª2010 Elsevier Inc.Most notably, the ectopic expression of XPO5 in the mutant
cells had cancer growth-inhibitor features (Figure 6). Upon trans-
fection of the wild-type XPO5 in HCT-15 mutant colorectal
cancer cells, the cells proved less viable in the MTT assay (Fig-
ure 6A) and had a markedly reduced percentage colony forma-
tion density (Figure 6B). Transfection of the XPO5Mut form in
HCT-15 cells was unable to reduce cell viability (Figure 6A) and
had no impact on the colony formation assay (Figure 6B). Over-
expression of XPO5 in the wild-type XPO5 colorectal cancer cell
line RKO was unable to reduce cell viability (Figure S5), under-
scoring the specific growth-inhibitory effect of XPO5 only in
XPO5 mutant cells. We next tested the ability of XPO5WT-trans-
fected HCT-15 cells to form tumors in nude mice compared with
empty vector transfected cells or with the XPO5Mut form (Fig-
ure 6C; Figure S5). HCT-15 XPO5 mutant cells transfected with
the empty vector or the mutant gene formed tumors rapidly,
but cells with wild-type XPO5 expression hadmuch lower tumor-
igenicity (Figure 6C; Figure S5). In sharp contrast, the stable
downregulation of XPO5 by the short hairpin RNA approach in
cells with wild-type XPO5 (RKO) was associated with increased
cell viability (Figure 6D), increased colony density formation (Fig-
ure 6E), and enhanced tumorigenicity in nude mice (Figure 6F;
Figure S5). The use of two additional different shRNAs against
XPO5 in RKO cells confirmed the observed enhancement of
cell viability and colony formation (Figure S5). Most importantly,
when we used siRNAs against XPO5 in cancer cells heterozy-
gous for the XPO5 mutation (HCT-15 and DLD-1), we observed
that the complete abrogation of XPO5 expression was toxic,
according to the XTT and trypan blue assays (Figure S5). These
findings are in agreement with the deleterious effects observed
upon the full abolishment of other miRNA processing genes
such asDICER1 (Bernstein et al., 2003), where a haploinsufficient
tumor-suppressor role has also been proposed (Kumar et al.,
2007, 2009; Hill et al., 2009; Lambertz et al., 2010). siRNA against
the mutant XPO5 transcript in HCT-15 and DLD1 cells did not
cause any evident effect in cell viability (Figure S5). Combined
siRNAs of wild-type and mutant XPO5 caused a similar cell
toxicity in XPO5 mutant cells than the one observed in single
siRNA of wild-type XPO5 (Figure S5).
Finally, we sought to measure the frequency of the described
XPO5 disruption in human primary tumors. We assessed
the XPO5 mutational status of 337 human primary malignancies
with microsatellite instability, including colorectal tumors arising
in those patients with germline defects in one mismatch
repair allele (HNPCC) (n = 38) and apparently sporadic colorectal
(n = 211), gastric (n = 58), and endometrial (n = 30) cancers where
mismatch repair gene function was somatically inactivated
(Table 1). We found thatXPO5 frameshift mutations were present
in 22.8% (77 of 337) of the primary tumors analyzed. The
described insertion of an ‘‘A’’ in the (A)7 coding microsatellite
repeat of exon 32 (Figure 1A) was found in 11.6% (39 of 337)
of cases. Interestingly, we discovered two other XPO5 frameshift
mutations in primary tumors that we did not observe in any cell
line: a deletion of an ‘‘A’’ in the same (A)7 coding microsatellite
repeat of exon 32 and a deletion of an ‘‘A’’ in an (A)4 repeat of
exon 32. These two mutations were present in 30 (8.9%) and 8
(2.4%) cases, respectively. The deletion of an ‘‘A’’ in the (A)7
repeat changes amino acid composition of the protein from
amino acids 1179–1193 and truncates the last 11 amino acids
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Figure 5. Restored miRNAs Expression and Function in XPO5WT Reconstituted Cells
(A) HeatMap depicting miRNA expression in XPO5 impaired cells (HCT-15 and DLD-1), XPO5 proficient cells (RKO and HCT-116), and XPO5WT transfected cells
(HCT-15 and DLD-1).
(B) Validation by qRT-PCR of the miRNA expression array data for six upregulated and five unchanged miRNAs upon XPO5WT transfection.
(C) Putative functional features according to the scientific literature of the 80 miRNAs upregulated upon XPO5WT transfection in mutant cells.
(D) Protein blot of miRNA target oncoproteins shows downregulation of EZH2, Myc and K-Ras exclusive in XPO5WT restored cells.
(E) Expression analysis of miR-200 miRNAs family targets analyzed by qRT-PCR. XPO5WT transfection in mutant cells causes a striking downregulation of ZEB1
(a very well-described target of the miR-200 family of miRNAs). As a secondary effect, the depletion of the transcriptional repressor ZEB1 causes an upregulation
of its targets CDH1, CRB3, INADL, and LGL2. Data shown represent mean ± SD, n = 3.
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Figure 6. Tumor-Suppressor Features of XPO5WT Protein
(A) The MTT assay showed that mutant XPO5 HCT-15 cells transfected with wild-type XPO5 are less viable than empty vector transfected cells (p = 0.0015).
Transfection with XPO5Mut did not affect cell viability. Data shown represent mean ± SD, n = 3.
(B) The colony formation assay showed that mutant XPO5 HCT-15 cells transfected with XPO5WT significantly formed fewer colonies than empty vector trans-
fected cells (*p < 0.001). Transfection with XPO5Mut did not affect colony formation. Data shown represent mean ± SD, n = 3.
(C) Effect of XPO5 transfection on the growth of HCT-15 cells in nude mice. Tumor volume was monitored over time and the tumor was excised and weighted at
30 days. There is a significant decrease in tumor volume and weight for the wild-type XPO5 transfected cells (left graphs, p = 0.008). Transfection of XPO5Mut did
not affect tumor growth of HCT-15 cells injected in nude mice (right graphs, p = 0.234). Data shown represent ± SEM, n = 10.
(D) RKO short-hairpin XPO5 transfected cells showed higher cell viability (p = 0.0012). Data shown represent mean ± SD, n = 3.
(E) Downregulation of XPO5 enhanced colony formation of RKO cells (p < 0.0001). Data shown represent mean ± SD, n = 3.
(F) RKO cells stably downregulated for XPO5 showed enhanced tumorigenic capacity (volume and weight) when injected into nude mice (p = 0.001). See also
Figure S5.
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Deficient Export of Pre-miRNAsof XPO5. The deletion of an ‘‘A’’ in the (A)4 repeat, also present in
exon 32, changes the amino acidic composition of the protein
from amino acids 1167–1205. We have cloned these two XPO5
mutations identified in the primary tumors and developed the
corresponding in vitro and in vivo assays. We have observed
that, upon transfection in XPO5mutant HCT-15 cells, bothmuta-
tions originate XPO5 proteins that at steady-state levels present
nuclear localization, are unable to enhance miRNA processing
efficiency, and do not affect cell viability (Figure S6). No single
tumor featured more than one mutation, which highlights the
functional relevance of each mutational event. Most importantly,
none of the 77 tumors with XPO5 mutations had a mutation in
TARBP2, the miRNA biogenesis gene also found alter in micro-
satellite unstable neoplams (Melo et al., 2009), a result that
emphasizes the unique role of XPO5 genetic defects in tumori-
genesis. No significant differences in XPO5 mutation frequency
were found between inherited and sporadic tumors or between
tumor types (Table 1). The described XPO5 mutations were not
present in primary colorectal tumors without microsatellite insta-312 Cancer Cell 18, 303–315, October 19, 2010 ª2010 Elsevier Inc.bility (0/42), normal colorectal mucosa (0/50), or in normal
lymphocytes from healthy donors (0/80) (Table 1). Thus, XPO5
mutations are common events in microsatellite unstable tumors
from the colon, stomach, and endometrium.
DISCUSSION
It is estimated that about 30% of human genes are putative
targets of miRNAs; hence, they exert a critical role in numerous
biological processes. Thus, it is not surprising that an aberrant
miRNA expression profile occurs in a wide range of human
diseases. This is particularly true for human cancer, in which
the expression of miRNAs is markedly deregulated (Lu et al.,
2005; Cummins et al., 2006). Like protein-coding genes, miRNAs
can act as tumor suppressors (Hammond, 2007) or oncogenes
(Esquela-Kerscher and Slack, 2006). Although the oncogenic
role of some particular miRNAs has been clearly demonstrated,
increasing evidence supports the concept that global downregu-
lation of mature miRNAs is a common hallmark of human tumors
Table 1. Frequency of XPO5 Mutations in Cancer Cell Lines,
Primary Tumors, and Normal Tissues
Sample Type Cell Lines Tissue Samples
Colon tumors from HNPCC — 10/38 (26.3%)
Sporadic colon tumors
(MSI+)
2/6 (33.3%) 47/211 (22.3%)
Sporadic gastric tumors
(MSI+)
— 16/58 (27.6%)
Sporadic endometrial
tumors (MSI+)
0/4 4/30 (13.3%)
Sporadic colon tumors
(MSI)
0/4 0/42
Normal colon — 0/50
Normal lymphocytes from
healthy donors
— 0/80
HNPCC, hereditary nonpolyposis colon cancer; MSI+, tumors with
microsatellite instability; MSI, tumors without microsatellite instability.
See also Figure S6.
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Deficient Export of Pre-miRNAs(Calin and Croce, 2006; Gaur et al., 2007; Lu et al., 2005). Many
explanations can be invoked to explain this phenotype, and,
herein, we propose another one: genetic defects in the nuclear
export machinery of pre-miRNAs. Our description of inactivating
mutations in XPO5, a key gene in the nuclear export of pre-miR-
NAs (Yi et al., 2003; Lund et al., 2004), highlights the relevance
of an intact export mechanism of miRNA-related molecules
to maintain the cellular homeostasis. The relevance of the
described genetic alteration in XPO5 in human cancer is sup-
ported by the observation of XPO5 deletions in different malig-
nancies (Zhang et al., 2008) and the described accumulation of
pre-miRNAs in particular cancer cell lines (Lee et al., 2008).
From a functional point of view in normal cells, the XPO5
protein continuously traverses the nuclear envelope (Brownawell
and Macara, 2002), for which reason it should be found in
the nuclear and cytoplasmic cellular compartments. However,
the described XPO5 mutations prevent XPO5 translocation
and ‘‘sequester’’ pre-miRNAs in the nucleus, clogging miRNA
biogenesis and function. Our data are in agreement with Yi
et al. (2003), where the knockdown of XPO5 caused diminished
levels of pre-miR-30 in the cytoplasmic fraction. Others have
already defined the pre-miRNA structural requirements for
binding toXPO5 (ZengandCullen, 2004). Pre-miRNAsare specif-
ically bound by XPO5 acting in concert with the GTP-bound form
of the Ran cofactor (Bohnsack et al., 2004) and this pre-miRNA/
XPO5/Ran-GTP ternary complex is recognized by proteins of
the nuclear pore complex. The XPO5mutant cancer form identi-
fied is still able to bind to the Ran protein, but binding cooperativ-
ity cargo-Ran has been lost due to the impaired pre-miRNA
recognition. Thus, subcellular distribution of XPO5 protein is
dependent, not only on Ran-GTP binding to its N-terminal region
(Bohnsack et al., 2004), but also to pre-miRNA binding. Interest-
ingly, Okada et al. (2009) has recently described the crystal struc-
ture of the complex formed between XPO5/Ran with the pre-
miRNAmolecule. Remarkedly, this structural study onlymodeled
residues1–1082of theXPO5protein, therefore leavinguncharac-
terized the residues altered in the XPO5Mut form present in
cancer, although it was suggested that the C-terminal of XPO5
was flexible (Okada et al., 2009). It is worth to consider that theCpre-miRNAused to prepare the recombinant complex for crystal-
lization was much shorter than the one used in our study, which
contains the stem loop and resembles the physiological pre-
miRNA molecule that is exported out of the nucleus. Therefore,
it is possible that the C-terminal region of XPO5 contributes to
the binding of the pre-miRNA fragment that is not contained
in the above mentioned crystal structure, because that section
of the pre-miRNA is missing in the reconstituted complex. In
fact, the structure deposited in the Protein Data Bank (pdb
3A6P) shows that the C-terminal region is close to the place
where the rest of the RNA molecule should be positioned. Alter-
natively, the cargo-binding defect observed in XPO5Mut might
be associatedwith adestabilization of the high-affinity conforma-
tion of XPO5 for pre-miRNA binding, which is also consistent
with our band-shift and isothermal titration microcalorimetry
data. Further research is warranted in this area.
Interestingly, from a potential translational point of view, the
exogenous introduction of wild-type XPO5 in mutant cancer
cells is able to restore the physiological nuclear export of pre-
miRNAs, and this XPO5 functional recovery is associated with
tumor growth inhibition properties. Most importantly, XPO5
transfection in mutant cells caused upregulation of miRNAs
with well-characterized tumor-suppressor features, such as
the miR-200 family, let-7a, and miR-26a, a finding that might
encourage the development of further strategies to restore the
expression of miRNAs with tumor-suppressor activities. The
development of more efficient delivery systems, such as ad-
enoassociated virus (AAV) vectors, has enabled significant
achievements in this area. For example, systemic AAV-mediated
delivery of miR-26a in a hepatocellular carcinoma mouse model
results in the remarkable suppression of tumorigenesis without
evident toxicity (Kota et al., 2009).
In conclusion, we provide evidence that inactivating mutations
of the pre-miRNA nuclear export gene XPO5 occur in human
tumors with microsatellite instability. The XPO5mutation causes
the trapping of pre-miRNAs in the nucleus and impairs the
production of maturemiRNAs in cancer cells, a phenotype that is
rescued by the reintroduction of the wild-type XPO5 gene. These
findings support a role of XPO5, as a candidate haploinsufficient
tumor-suppressor gene, and suggest that strategies directed
toward stimulating the activity of miRNA processing factors
and restoring the production of miRNAs with growth inhibitory
activities might have a therapeutic value.
EXPERIMENTAL PROCEDURES
Cell Lines and Primary Tumor Samples
Human colorectal and endometrial cancer cell lines were obtained from the
American Type Culture Collection. Human gastric cancer cell lines and
Co115 were kindly provided by Dr. Minoru Toyota (First Department of Internal
Medicine, Sapporo Medical University, Japan) and Dr. Richard Hamelin
(INSERM, Paris, France), respectively. DNA samples from primary tumors
(n = 337) were obtained at the time of the clinically indicated surgical proce-
dures. All patients provided informed consent and the study was conducted
under the approval of the Institutional Review Boards of Vall d’Hebron Univer-
sity Hospital and Sapporo Medical University.
RNA Isolation, Quantification of miRNAs by Real-Time PCR and
miRNA Expression Microarray
Total RNA was isolated by Trizol (Invitrogen, San Diego, CA). Extraction was
carried out according to the manufacturer’s instructions. Nuclear andancer Cell 18, 303–315, October 19, 2010 ª2010 Elsevier Inc. 313
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Deficient Export of Pre-miRNAscytoplasmic RNA were extracted using the Cytoplasmic and Nuclear RNA
purification kit from NORGEN following the manufacturer’s instructions. All
RNA samples were DNase-treated (Turbo DNA-free, Ambion, Austin, TX). Taq-
Man MiRNA assays were used to quantify the level of mature miRNAs, as
previously described (Melo et al., 2009). Pre-miRNAs processing efficiency
calculations are provided in Supplemental Experimental Procedures. The
miRNA expression study by microarray analysis was developed as previously
described (Melo et al., 2009). Supplemental Experimental Procedures provide
further details.
Plasmids, Protein Purification, and Protein Analysis
Protein blotting and confocal microscopy were developed as described in
Supplementary Experimental Procedures. The pcDNA3.1+XPO5WT,
pcDNA3.1+XPO5Mut, pcDNA3.1+XPO5Del.A(A)7, and pcDNA3.1+XPO5Del.A(A)4
expression plasmids were obtained as described in Supplementary Experi-
mental Procedures. GST-Ran, XPO5WT-His6, XPO5
Mut-His6, and XPO5
D108-
His6 were expressed in E. coli BL21 (DE3) strain. GST fusion Ran was purified
on a glutathione-Sepharose column (Amersham Biosciences) and eluted with
50 mM reduced glutathione. Polyhistidine-tagged proteins were purified using
nickel-chelating beads (Millipore) and eluted with 200 mM imidazole. Ran/
XPO5 interaction and western blot analysis (monoclonal anti-His-Tag 1:1000,
Abcam; monoclonal anti-His-Tag biotin conjugated 1:2000) were done as
described (Ching et al., 2006). Electrophoretic mobility shift assay was done
as described (Yi et al., 2003).
Transfection and Luciferase Assays
pcDNA3.1+pcDNA3.1+XPO5WT, pcDNA3.1+XPO5Mut, pcDNA3.1+XPO5Del.A(A)7,
pcDNA3.1+XPO5Del.A(A), pRS-shXPO5, pGFP, pRS-shGFP, pRS-GFP-empty
vector, and pRS-GFPneo-miR-15-16 expression plasmids were transfected by
electroporating 67 cells in 0.4 ml PBS with 20 mg of the expression plasmid at
250 V and 975 mF. Stable clones expressing XPO5WT and XPO5Mutwere selected
in complete DMEM medium supplemented with 1 mg ml-1 G418. Stable clones
expressing GFP, miR-15/16, shXPO5, and shGFP were selected in complete
DMEM medium supplemented with 0.5 mg ml-1 puromycin. For the luciferase
reporter experiments pGL3_Bcl2WT vector (Calin et al., 2008) was used in
pRS-GFPneo-miR-15-16 stably transfected cell lines according to the manufac-
turer’s instructions (Promega).
Cell Viability, Colony Formation Assay, and In Vivo Nude Mouse
Tumor-Growth Assay
Cell viability was determined by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-
2H-tetrazolium bromide (MTT) assay. For colony formation experiments,
stable G418, Puromycin and G418 + Puromycin-resistant colonies were fixed
and stained with MTT reagent. In vivo nude mouse tumor-growth assays were
developed as described in Supplemental Experimental Procedures. All animal
experiments were approved by the Bellvitge Biomedical Research Institute
(IDIBELL) Ethical Committee and performed in accordance with the guidelines
stated in The International Guiding Principles for Biomedical Research
involving Animals, developed by the Council for International Organizations
of Medical Sciences (CIOMS).
ACCESSION NUMBERS
miRNA-chip data have been deposited into ArrayExpress under accession
number E-MTAB-160.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Experimental Procedures, six figures, and
one table and can be found online at doi:10.1016/j.ccr.2010.09.007.
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